Posted by Michael Wonder on 06 Jul 2022
Health Canada approves HyQvia, a new treatment for Canadians with immune deficiencies
6 July 2022 - New immunoglobulin treatment offers Canadian patients option of subcutaneous once-monthly (every three or four weeks) dosing.
Takeda Canada is pleased to announce that Health Canada has issued the marketing authorisation (Notice of Compliance) for HyQvia (normal immunoglobulin (human) 10% & recombinant human hyaluronidase solution for subcutaneous infusion) as replacement therapy for primary humoral immunodeficiency and secondary humoral immunodeficiency in adult patients.
